Home Shop Science About View Cart →
Home › Fat Loss › Tesamorelin
GHRH Analogue · SubQ 99%+ Purity Tesamorelin
Fat Loss Hormones Performance

Tesamorelin

Tesamorelin — FDA-cleared GHRH analogue specifically developed for visceral fat reduction, with the most robust clinical dataset of any GH secretagogue.

★★★★☆ 4.7 · 44 verified reviews · See all
Price range: $97.00 through $340.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • FDA-cleared for HIV-associated lipodystrophy — strongest clinical evidence of any GH secretagogue
  • Preferential visceral fat reduction — targets the metabolically dangerous abdominal depot
  • Stimulates pituitary GH release — preserves hypothalamic-pituitary axis
  • Improves triglycerides, IGF-1, and trunk-to-limb fat ratio
  • Daily subcutaneous injection with predictable and reproducible effect
Community Insights

Why people research Tesamorelin

These are the specific situations and goals that lead researchers to Tesamorelin. For research purposes only.

01
Treating HIV-associated lipodystrophy
the FDA-approved indication under Egrifta for abdominal fat accumulation from antiretroviral therapy
02
Reducing visceral abdominal fat in men who've failed diet and exercise
Tesamorelin's phase 3 trial data showing visceral fat reduction is the primary appeal outside of HIV
03
Getting the most clinically validated GHRH peptide available
the Egrifta trial package represents more human data than any other GHRH analogue
04
Improving cognitive function alongside body composition
a secondary finding of the clinical trials showing cognitive benefits in the tesamorelin arm
05
Reducing hepatic fat in MASH/NAFLD when GLP-1s or lifestyle changes alone have not reduced liver enzyme markers
06
Adding GH axis support to a TRT protocol without taking pharmaceutical somatropin
07
Achieving visceral fat reduction at better tolerability and lower cost than exogenous HGH therapy
08
Improving IGF-1 levels and body composition in men with age-related GH decline who want a clinically validated approach
09
Using the most regulated GHRH peptide before considering less-studied options like CJC-1295 or Sermorelin
10
Managing metabolic complications of long-term antiretroviral therapy
lipid redistribution and metabolic syndrome driven by ART medication
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 2mg vial + 2mL BAC water
Suggested Cycle Length
16–26 weeks
For research reference only

⚠ For research reference only. Tesamorelin is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Tesamorelin Vial

Your selected amount of lyophilized Tesamorelin in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Tesamorelin Works

The mechanism of action, step by step.

01

Stabilised GHRH Binding

Tesamorelin is a GHRH(1-44) analogue with a trans-3-hexenoic acid modification that prevents enzymatic degradation, giving it a longer half-life than native GHRH while preserving full GHRH receptor binding.

02

Pulsatile GH Stimulation

Daily tesamorelin injection stimulates pulsatile GH release from the pituitary via the GHRH receptor, elevating mean GH and downstream IGF-1 in a physiological pattern — distinct from continuous exogenous HGH administration.

03

Preferential Visceral Fat Mobilisation

GH elevation from tesamorelin activates hormone-sensitive lipase preferentially in visceral adipose tissue, which has higher GH receptor density than subcutaneous fat — explaining the compound's specific efficacy for abdominal fat.

04

Metabolic Improvement

Reduction in visceral adipose tissue produces secondary improvements in triglycerides, insulin sensitivity, and systemic inflammation, as visceral fat is the primary contributor to atherogenic dyslipidaemia and metabolic syndrome.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Standard Dose
2000 mcg (2 mg)
Once daily, bedtime preferred
Timing
Fasted or 2 hrs post-meal
Avoid carbohydrate meals around injection
FDA Protocol
2 mg daily
Dose used in all pivotal clinical trials
Cycle Length
6–12 months
Visceral fat reduction continues for full duration
Break
2–3 months
Fat typically returns gradually on discontinuation
Monitoring
Waist circumference + IGF-1
Primary outcome measure every 12 weeks
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Tesamorelin.

1

Tesamorelin in HIV-associated abdominal adiposity (EGRIFTA pivotal trial)

Tesamorelin 2 mg daily reduced visceral adipose tissue by 15.2% at 26 weeks and 18.5% at 52 weeks versus placebo, with significant improvements in triglycerides and waist circumference, leading to FDA approval.

New England Journal of Medicine, 2010
2

Visceral fat reduction and metabolic markers with tesamorelin in non-HIV adults

In obese adults without HIV, tesamorelin significantly reduced visceral fat mass by 12-15% over 26 weeks with improvements in triglycerides and trunk-to-limb fat ratio — supporting its use in general obesity-related visceral fat accumulation.

Annals of Internal Medicine, 2012
3

Tesamorelin effects on cognitive function — secondary analysis

Post-hoc analysis of tesamorelin-treated patients showed improvements in executive function and verbal memory correlated with IGF-1 elevation, suggesting GH optimisation via GHRH agonism may have cognitive benefits beyond body composition.

Journal of Clinical Endocrinology and Metabolism, 2020
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
S
Sandra L.
Toronto, ON · Visceral Fat
★★★★★
✓ Verified Purchase
The best compound for visceral fat

Had stubborn abdominal fat that did not respond to diet. Three months of tesamorelin and my waist is down 4 cm with no changes to my diet. The clinical data is real.

C
Craig M.
Vancouver, BC · Metabolic Health
★★★★★
✓ Verified Purchase
FDA data backs it up

The EGRIFTA trial convinced me this was worth trying. Results have matched the clinical data. Waist circumference down 5 cm at 4 months, IGF-1 elevated appropriately, no significant side effects.

D
Diane W.
Calgary, AB · Body Composition
★★★★☆
✓ Verified Purchase
Slow but genuine change

Visceral fat does not disappear overnight but by month 3 the change was clearly visible. Triglycerides also came down significantly in my quarterly blood work. Would run indefinitely.

Common Questions

Frequently Asked Questions

Tesamorelin is the only GHRH analogue with FDA clearance (for HIV lipodystrophy) and has the most extensive clinical dataset of any GH secretagogue. Its modification specifically improves stability versus native GHRH, and clinical trials have consistently demonstrated preferential visceral fat reduction.
Tesamorelin's clinical trials show preferential reduction in visceral fat — the deep abdominal fat surrounding organs. Subcutaneous fat is less affected. This is because visceral adipose tissue has higher GH receptor density.
2 mg (2000 mcg) daily subcutaneous injection is the dose used in all pivotal clinical trials and the FDA-approved regimen. This is the standard research dose.
Bedtime in the fasted state is standard practice. Tesamorelin's GHRH activity amplifies the nocturnal GH pulse, and food — particularly carbohydrates — blunts GH release.
Clinical trials show visceral fat begins returning toward baseline within weeks of discontinuation. Ongoing use is required to maintain the effect — similar to any GH axis intervention.
Yes — GHRH plus ghrelin-axis synergy applies to tesamorelin as it does to CJC-1295. Adding ipamorelin produces synergistic GH pulses for greater IGF-1 elevation and enhanced results.
Tesamorelin Tesamorelin
Price range: $97.00 through $340.00